---
title: Bacterial Vaginosis
permalink: /bacterial-vaginosis/
variant: tiptap
description: ""
third_nav_title: A to F
---
<div data-type="detailGroup" class="isomer-accordion isomer-accordion-white">
<details class="isomer-details">
<summary><strong>Overview/Background</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p>Bacterial vaginosis (BV) is a common condition in women characterized
by an imbalance of microorganisms in the vagina. In cases of BV, there
is a decrease in the number of normal hydrogen peroxide-producing <em>Lactobacillus </em>species
and an excessive growth of anaerobic bacteria, such as <em>Gardnerella spp.</em>,&nbsp;<em>Prevotella spp., Mobilincus spp., Ureaplasma urealyticum and Mycoplasma hominis, leading to an increase in pH from less than 4.5 to as high as 7.0.</em>
</p>
<p><em>&nbsp;</em>
</p>
<p><em>BV is not considered a sexually transmitted infection, but it does occur more commonly in sexually active women. </em>The
exact role of sexual transmission in the pathogenesis of BV vaginal dysbiosis
is unclear.</p>
<p></p>
</div>
</details>
<details class="isomer-details">
<summary><strong>Disease Epidemiology</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p>BV is the most common vaginal infection found in women of reproductive
age and is estimated to occur in anywhere from 5 to 70% of women. Globally,
it is more commonly reported in low-resource settings and areas with limited
access to healthcare.</p>
</div>
</details>
<details class="isomer-details">
<summary><strong>Pathogen(s)</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p>The organisms most commonly associated with BV are&nbsp;<em>G. vaginalis, Bacteroides spp, Prevotella</em> spp.,&nbsp;<em>Mobiluncus</em>&nbsp;spp<em>.,</em>  <em>Ureaplasma </em>urealyticum<em> </em>and&nbsp;<em>Mycoplasma hominis.</em>
</p>
</div>
</details>
<details class="isomer-details">
<summary><strong>Transmission</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p><em>BV is not considered a sexually transmitted infection, but it does occur more commonly in sexually active women. </em>The
exact role of sexual transmission in the pathogenesis of BV vaginal dysbiosis
is unclear.</p>
<p><strong>Incubation period</strong>: 4 days</p>
<p><strong>Infectious period: </strong>NA</p>
</div>
</details>
<details class="isomer-details">
<summary><strong>Clinical features</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p>BV may be asymptomatic. Common symptoms include:</p>
<ul data-tight="true" class="tight">
<li>
<p>unusual vaginal discharge that is thin and grayish-white</p>
</li>
<li>
<p>a fishy odour from the vagina, especially after sex</p>
</li>
<li>
<p>itching or irritation around the vagina</p>
</li>
<li>
<p>burning during urination</p>
</li>
</ul>
<p>&nbsp;</p>
<p>At times, BV will go away without treatment. However, if untreated it
can lead to:</p>
<ul data-tight="true" class="tight">
<li>
<p>problems in pregnancy (for example, spontaneous abortion and preterm delivery
for pregnant women with BV)</p>
</li>
<li>
<p>higher risk of STIs and HIV</p>
</li>
<li>
<p>pelvic inflammatory disease</p>
</li>
</ul>
</div>
</details>
<details class="isomer-details">
<summary><strong>Risk factors</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p>Risk factors include:</p>
<ul data-tight="true" class="tight">
<li>
<p>vaginal douching</p>
</li>
<li>
<p>receptive cunnilingus</p>
</li>
<li>
<p>recent change of sex partner</p>
</li>
<li>
<p>smoking</p>
</li>
<li>
<p>presence of an STI</p>
</li>
</ul>
</div>
</details>
<details class="isomer-details">
<summary><strong>Diagnosis</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<table style="minWidth: 25px">
<colgroup>
<col>
</colgroup>
<tbody>
<tr>
<td rowspan="1" colspan="1">
<p></p>
<p>BV is often diagnosed by the Amsel criteria, with at least three of the
four criteria should be present:</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thin homogenous vaginal
discharge that coats the vaginal wall and vestibule</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pH of vaginal fluid
&gt; 4.5</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Positive amine (fish-like)
odour test (“whiff test”) before or after addition of 10% KOH</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Presence of clue cells
on microscopy of vaginal discharge.</p>
</td>
</tr>
</tbody>
</table>
</div>
</details>
<details class="isomer-details">
<summary><strong>Treatment and Management</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p></p>
</div>
</details>
</div>
<p></p>
<p>&nbsp;</p>
<p></p>
<p></p>
<p></p>
<p></p>
<p>
<br>
</p>
<table style="minWidth: 25px">
<colgroup>
<col>
</colgroup>
<tbody>
<tr>
<td rowspan="1" colspan="1">
<p></p>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<p></p>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<p></p>
<p>Patients should be asked to avoid vaginal douching, use of shower gels,
antiseptic agents or shampoos in the bath.</p>
<p>&nbsp;</p>
<p>Recommended regimens for BV:</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Metronidazole&nbsp;400-</strong>500
mg orally 2 times/day for 5 to 7 days or</p>
<p><strong>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metronidazole 2g orally single dose or</strong>
</p>
<p><strong>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metronidazole gel 0.75%</strong>&nbsp;one
full applicator (5 g) intravaginally daily for 5 days or</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Clindamycin cream 2%</strong>&nbsp;one
full applicator (5 g) intravaginally at bedtime for 7 days</p>
<p>Recommended regimens for BV in pregnancy:</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Metronidazole&nbsp;400-</strong>500
mg orally 2 times/day for 7 days or</p>
<p><strong>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metronidazole 200mg orally 3 times/day for 7 days or</strong>
</p>
<p><strong>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clindamycin 300mg orally 2 times/day for 7 days</strong>
</p>
<p>Follow-up is not necessary if symptoms resolve. For high-risk pregnant
women, a one-month follow-up visit is recommended to evaluate if treatment
is successful. Long-term maintenance regimens are not recommended.</p>
<p>Alternative regimen can be given for recurrent disease. Please refer to
<a href="https://www.nsc.com.sg/dsc/healthcare-professionals/publications/Pages/STI-Management-Guidelines.aspx" rel="noopener noreferrer nofollow" target="_blank">DSC’s website</a>for more information on alternative regimens.</p>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<p><strong>Precaution, Prevention and Control</strong>
</p>
<p>The cause of BV is not yet understood. The following basic preventive
measures may help lower the risk of getting BV:</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid douching and feminine
sprays</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not having sex</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Limit the number of
sex partners</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use condoms consistently</p>
<p><strong>&nbsp;</strong>
</p>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<p><strong>Notification</strong>
</p>
<p>BV is not a notifiable condition.</p>
<p>&nbsp;</p>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<p><strong>Resources</strong>
</p>
<p>Please refer to <a href="https://www.nsc.com.sg/dsc/healthcare-professionals/publications/Pages/STI-Management-Guidelines.aspx" rel="noopener noreferrer nofollow" target="_blank">DSC’s website</a> for
more information on alternative regimens.</p>
<p><strong>&nbsp;</strong>
</p>
<p><strong>References</strong>
</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Department of Sexually
Transmitted Infections Control (DSC). STI management guidelines 7<sup>th</sup> edition.
2021.</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Javed A, Parvaiz F,
Manzoor S.&nbsp;Bacterial&nbsp;vaginosis: An insight into the prevalence,
alternative treatments regimen and its associated resistance patterns.&nbsp;Microb
Pathog.&nbsp;2019 Feb;127:21-30.</p>
<p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; World Health Organization.
Bacterial vaginosis. 2023.</p>
<p>&nbsp;</p>
</td>
</tr>
</tbody>
</table>
<p></p>